Wednesday, September 16, 2026

Pharmaceutical Investment

1 article

Oncology Pipeline Surge Through 2026-2027 Drives Biotech Valuations as Novel Mechanisms Target NSCLC

Multiple oncology drug candidates are advancing toward FDA approval in 2026-2027, with concentrated activity in non-small cell lung cancer therapeutics. Novel approaches including antibody-drug conjugates, targeted radiopharmaceuticals, and immune checkpoint inhibitors represent critical inflection points for biotechnology valuations. Regeneron's strategic entry into radiopharmaceuticals and clinical progress from emerging biotechs signal investor confidence in pipeline strength.

LM Salvado•Apr 18, 2026

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

AI's 'Show-Me' Reckoning: Earnings Divergence, Executive Exodus, and Regulatory Tightening

Investors are shifting from rewarding AI narratives to demanding tangible results, evidenced by Adobe's weak guidance despite user-growth emphasis, Palantir's stock decline even after winning the Army's TITAN contract, and UiPath's contrasting guidance raise. Simultaneously, high-profile safety-driven departures from Anthropic and Google, plus new regulatory actions (California's under-16 social media ban, Anthropic's misuse-blocking disclosures), signal mounting scrutiny of AI's societal and financial risk profile even as fintech-adjacent funding (Socure) continues.

Our read on the data ›

Signals we're tracking

Satellite-Terrestrial Network Integration Acceleration

Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases

Patterns we're watching ›

Where sources disagree

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,981

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,981 facts checked against source5,288 source documents archived

Query this data → isubstrate.com